Log In
Print this Print this

Vanihep, vaniprevir (MK-7009)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionHCV NS3/4A protease complex inhibitor
Molecular Target HCV NS3/4A protease complex
Mechanism of ActionViral protease inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV infection
Regulatory Designation Japan - Standard Review (Treat HCV infection)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today